Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 46-52 , January 2010

A secondary prevention lipid clinic reaches low-density lipoprotein cholesterol goals more often than usual cardiology care with coronary heart disease

  • Kim K. Birtcher, MS, PharmD

      Affiliations

    • University of Houston College of Pharmacy, Houston, TX
    • ,
  • Anthony J. Greisinger, PhD

      Affiliations

    • Kelsey Research Foundation, 5615 Kirby Drive, Suite 660, Houston, TX 77005
    • Corresponding Author InformationCorresponding author.
    • ,
  • Brenda J. Brehm, MA

      Affiliations

    • Kelsey Research Foundation, 5615 Kirby Drive, Suite 660, Houston, TX 77005
    • ,
  • Oscar A. Wehmanen, MS

      Affiliations

    • Kelsey Research Foundation, 5615 Kirby Drive, Suite 660, Houston, TX 77005
    • ,
  • Loriann M. Furman, PharmD

      Affiliations

    • Kelsey-Seybold Clinic, Houston, TX
    • ,
  • Cathryn C. Salinas, RPh

      Affiliations

    • Kelsey-Seybold Clinic, Houston, TX
    • ,
  • Madjid Mirzai-Tehrane, MD

      Affiliations

    • Kelsey-Seybold Clinic, Houston, TX
    • ,
  • Atasu Nayak, MD

      Affiliations

    • Kelsey-Seybold Clinic, Houston, TX
    • ,
  • Haroonur Rashid, MD

      Affiliations

    • Kelsey-Seybold Clinic, Houston, TX
    • ,
  • Ali Mortazavi, MD

      Affiliations

    • Kelsey-Seybold Clinic, Houston, TX

Received 14 September 2009 ,Accepted 3 December 2009.

References 

  1. American Heart Association. Heart Disease and Stroke Statistics—2008 Update. Dallas, TX: American Heart Association; 2008;
  2. National Cholesterol Education Panel, Adult Treatment Panel III. JAMA. 2001;285:2486–2497
  3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–732
  4. Smith SC, Allen J, Blair SN. AHA/ACC; National Heart, Lung and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute. Circulation. 2006;113:2363–2372
  5. LaRosa JC, Cleeman JI. Cholesterol lowering as a treatment for established coronary heart disease. Circulation. 1992;85:1229–1235
  6. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781–1791
  7. Strechtman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197–204
  8. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI). Arch Inter Med. 1997;157:2413–2446
  9. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  10. The Vesthold Heartcare Study Group. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2003;10:429–437
  11. McLeod AL, Brooks L, Taylor V, Currie PF, Dewhurst NG. Secondary prevention for coronary artery disease. Q J Med. 2004;97:127–131
  12. Meade LT. Barriers to Achieving LDL cholesterol goals. US Pharmacist. 2007;32:66–71
  13. Mazzolini TA, Irons BK, Schell EC, Seifer CF. Use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA medical centers. J Manag Care Pharm. 2005;11:763–771
  14. Schectman G, Wolff N, Byrd JC, Hiatt JG, et al. Physician extenders for cost-effective management of hypercholesterolemia. J General Intern Med. 1996;11:277–286
  15. Shaffer J, Wexler J. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system: results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med. 1995;155:2330–2335
  16. Blum BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: hyperlipidemia. J Am Pharm Assoc. 2000;40:157–165
  17. Brown AS, Cofer LA. Lipid management in a private cardiology practice (the Midwest heart experience). Am J Cardiol. 2000;85:18A–22A
  18. Merenich JA, Lousberg TR, Brennan SH, et al. Optimizing treatment of dyslipidemia in patients with coronary artery disease in a managed care environment. Am J Cardiol. 2000;85:36A–42A
  19. Vivian E. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002;22:1533–1540
  20. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med. 2002;162:1149–1155
  21. Faulkner MA, Wadibia EC, Lucus BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination of lipid-lowering therapy in patients undergoing coronary artery revascularization, a randomized controlled clinical trial. Pharmacotherapy. 2000;20:410–416
  22. O'Donnell DC, Chen WT, Piziak VK. Goal attainment and maintenance of serum cholesterol level in a pharmacist-coordinated lipid clinic. Am J Health Systems Pharmacists. 2001;58:325–330
  23. Cording MA, Engelbrecht-Zadvorny EB, Pettit BJ, Eastham JH, et al. Development of a pharmacist-managed lipid clinic. Ann Pharmacother. 2002;36:892–904
  24. Till LT, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm. 2003;9:269–273
  25. Borenstein JD, Graber G, Saltiel E, Walace J, et al. Physician-pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy. 2003;23:209–216
  26. Olson KL, Rasmussen J, Sandhoff BG. Merenich JA for the Clinical Pharmacy Cardiac Risk Service (CPCRS) Study Group. Lipid Management in Patients with Coronary Artery Disease by a Clinical Pharmacy Service in a Group Model Health Maintenance Organization. Arch Intern Med. 2005;165:49–54
  27. Collins C, Kramer A, O'Day ME, Low MB. Evaluation of patient and provider satisfaction with a pharmacist-managed lipid clinic in a Veterans Affairs medical center. Am J Health-Syst Pharm. 2006;63:1723–1727
  28. Becker DM, Raquerno JV, Yook RM, et al. Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease. Arch Intern Med. 1998;158:1533–1539
  29. Murchie P, Campbell NC, Ritchie LD, Simpson JA, et al. Secondary prevention clinics for coronary heart disease: four year follow up of a randomized controlled trial in primary care. BMJ. 2003;326:84
  30. Robinson JG, Conroy C, Wickemeyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol <100mg/dL. Am J Cardiol. 2000;85:305–308
  31. Mainie PM, Moore G, Riddell JW, Adgey AA. To examine the effectiveness of a hospital-based nurse-led secondary prevention clinic. Eur J Cardiovasc Nurs. 2005;4:308–313
  32. Berna GMS, van der Bijl JJ, Banga JD, Visseren FLJ. Vascular risk management through nurse-led self-management programs. J Vasc Nurs. 2005;23:20–24
  33. American Heart Association. How Do I Follow A Healthy Diet? c2007. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3004832. Accessed December 8, 2009
  34. American Heart Association. Why Should I Be Physically Active? c2007. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3009620. Accessed December 8, 2009
  35. American Heart Association. How Can I Quit Smoking? c2007. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3004837. Accessed December 8, 2009
  36. Chou AF, Hudson Scholle S, et al. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Women's Health Issues. 2007;17:120–130
  37. Shammas NW, Lemke JH, Deckert J, Toth PP, McKinney D, Dippel EJ. Gender differences in adhering to national guidelines in a community lipid clinic. Prev Cardiol. 2006;9:215–218
  38. Santos RD, Waters DD, Tarasenko L, et al. on behalf of the L-TAP 2 investigators. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: the Lipid Treatment Assessment Project (L-TAP) 2. Am Heart J. 2009;158:860–866

PII: S1933-2874(09)00443-7

doi: 10.1016/j.jacl.2009.12.001

Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 46-52 , January 2010

Article Tools